The evolving role of plerixafor in hematopoietic progenitor cell mobilization

Transfusion

Volumn 53, Issue 10, 2013, Pages 2314-2326

  Tanhehco, Yvette C ^a   Vogl, Dan T ^b   Stadtmauer, Edward A ^b   O'Doherty, Una ^b  

^a Columbia University New York ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ACUTE LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BONE PAIN; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; NAUSEA; ORAL PARESTHESIA; REVIEW; SINUS TACHYCARDIA; STEM CELL MOBILIZATION;

COST-BENEFIT ANALYSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKEMIA; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84885841509     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12102     Document Type: Review

References (92)

1. Goodman JW, Hodgson GS,. Evidence for stem cells in the peripheral blood of mice. Blood 1962; 19: 702-714.
2. Richman CM, Weiner RS, Yankee RA,. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-1039.
3. Kessinger A, Armitage JO, Landmark JD, Smith DM, Weisenburger DD,. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-727.
4. Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K, Gooley T, Demirer T, Schiffman K, Weaver C, Clift R, Chauncey T, Klarnet J, Montgomery P, Petersdorf S, Weiden P, Witherspoon R, Buckner CD,. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
5. Raghavachar A, Prummer O, Fliedner TM, Calvo W, Steinbach IB,. Stem cells from peripheral blood and bone marrow: a comparative evaluation of the hemopoietic potential in the dog. Int J Cell Cloning 1983; 1: 191-205. (Pubitemid 14233280)
6. Zander AR, Lyding J, Bielack S,. Transplantation with blood stem cells. Blood Cells 1991; 17: 301-309.
7. Janssen WE,. Peripheral blood and bone marrow hematopoietic stem cells: are they the same? Semin Oncol 1993; 20: 19-27. (Pubitemid 23321482)
8. Champlin RE,. Peripheral blood progenitor cells: a replacement for marrow transplantation? Semin Oncol 1996; 23: 15-21. (Pubitemid 26127205)
9. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD,. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-1198.
10. Duhrsen U, Villeval JL, Boyd J, Kannourakis G, Morstyn G, Metcalf D,. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081. (Pubitemid 19030905)
11. Gianni AM, Siena S, Bregni M, Tarella C, Stern AC, Pileri A, Bonadonna G,. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585. (Pubitemid 19216206)
12. To LB, Haylock DN, Simmons PJ, Juttner CA,. The biology and clinical uses of blood stem cells. Blood 1997; 89: 2233-2258. (Pubitemid 27143269)
13. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, Kurtzberg J,. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719. (Pubitemid 23101582)
14. Rosenbeck LL, Srivastava S, Kiel PJ,. Peripheral blood stem cell mobilization tactics. Ann Pharmacother 2010; 44: 107-116.
15. Weaver CH, Schulman KA, Wilson-Relyea B, Birch R, West W, Buckner CD,. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 2000; 18: 43-53. (Pubitemid 30036335)
16. Koc ON, Gerson SL, Cooper BW, Laughlin M, Meyerson H, Kutteh L, Fox RM, Szekely EM, Tainer N, Lazarus HM,. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-1830. (Pubitemid 30261919)
17. Lane TA, Ho AD, Bashey A, Peterson S, Young D, Law P,. Mobilization of blood-derived stem and progenitor cells in normal subjects by granulocyte-macrophage- and granulocyte-colony-stimulating factors. Transfusion 1999; 39: 39-47. (Pubitemid 29065958)
18. Lane TA, Law P, Maruyama M, Young D, Burgess J, Mullen M, Mealiffe M, Terstappen LW, Hardwick A, Moubayed M,. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995; 85: 275-282.
19. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, Habler L, Ponomaryov T, Taichman RS, Arenzana-Seisdedos F, Fujii N, Sandbank J, Zipori D, Lapidot T,. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002; 3: 687-694. (Pubitemid 34752479)
20. Nervi B, Link DC, DiPersio JF,. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006; 99: 690-705. (Pubitemid 44521989)
21. Kessans MR, Gatesman ML, Kockler DR,. Plerixafor: a peripheral blood stem cell mobilizer. Pharmacotherapy 2010; 30: 485-492.
22. Jantunen E,. Novel strategies for blood stem cell mobilization: special focus on plerixafor. Expert Opin Biol Ther 2011; 11: 1241-1248.
23. Nazha A, Cook R, Vogl DT, Mangan PA, Gardler M, Hummel K, Cunningham K, Luger SM, Porter DL, Schuster S, O'Doherty U, Siegel D, Stadtmauer EA,. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant 2011; 46: 59-63.
24. Fitoussi O, Perreau V, Boiron JM, Bouzigon E, Cony-Makhoul P, Pigneux A, Agape P, Nicolini F, Dazey B, Reiffers J, Salmi R, Marit G,. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001; 27: 837-842. (Pubitemid 32496417)
25. Hiwase DK, Bollard G, Hiwase S, Bailey M, Muirhead J, Schwarer AP,. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007; 9: 539-547. (Pubitemid 47457005)
26. Sheppard D, Bredeson C, Allan D, Tay J,. Systematic review of randomized controlled trials of hematopoietic stem cell mobilization strategies for autologous transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2012; 18: 1191-1203.
27. Motabi IH, Dipersio JF,. Advances in stem cell mobilization. Blood Rev 2012; 26: 267-278.
28. Hamadani M, Kochuparambil ST, Osman S, Cumpston A, Leadmon S, Bunner P, Watkins K, Morrison D, Speir E, Deremer D, Kota V, Jillella A, Craig M, Awan F,. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 2012; 18: 1128-1135.
29. Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G,. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010; 45: 39-47.
30. Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG,. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009; 23: 1904-1912.
31. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G,. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
32. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Fruehauf S, Horwitz M, Cooper D, Bridger G, Calandra G,. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
33. Fowler CJ, Dunn A, Hayes-Lattin B, Hansen K, Hansen L, Lanier K, Nelson V, Kovacsovics T, Leis J, Calandra G, Maziarz RT,. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009; 43: 909-917.
34. Liles WC, Rodger E, Broxmeyer HE, Dehner C, Badel K, Calandra G, Christensen J, Wood B, Price TH, Dale DC,. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005; 45: 295-300. (Pubitemid 40389423)
35. Cashen A, Lopez S, Gao F, Calandra G, MacFarland R, Badel K, DiPersio J,. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biol Blood Marrow Transplant 2008; 14: 1253-1261.
36. Rettig MP, Lopez S, McFarland K, DiPersio J,. Rapid and prolonged mobilization of human CD34+ hematopoietic stem cells following intravenous (IV) administration of plerixafor. 53rd ASH Annual Meeting and Exposition. Orlando, FL, 2010: Poster 2261.
37. Cashen A, Rettig MP, Gao F, Reineck T, Abboud CN, Stockerl-Goldstein KE, Vij R, Uy GL, Westervelt P, DiPersio J,. Phase I/II study of intravenous plerixafor added to a mobilization regimen of G-CSF in lymphoma patients undergoing autologous stem cell collection. Biol Blood Marrow Transplant 2012; 18: S205.
38. Basak GW, Jaksic O, Koristek Z, Mikala G, Basic-Kinda S, Mayer J, Masszi T, Giebel S, Labar B, Wiktor-Jedrzejczak W,. Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells. Eur J Haematol 2011; 86: 488-495.
39. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G,. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874. (Pubitemid 41208607)
40. Hubel K, Liles WC, Broxmeyer HE, Rodger E, Wood B, Cooper S, Hangoc G, Macfarland R, Bridger GJ, Henson GW, Calandra G, Dale DC,. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004; 1: 165-172.
41. Micallef IN, Ho AD, Klein LM, Marulkar S, Gandhi PJ, McSweeney PA,. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011; 46: 350-355.
42. Salman H, Lazarus HM,. Plerixafor for autologous CD34 cell mobilization. Core Evid 2011; 6: 23-29.
43. Stiff P, Micallef I, McCarthy P, Magalhaes-Silverman M, Weisdorf D, Territo M, Badel K, Calandra G,. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol Blood Marrow Transplant 2009; 15: 249-256.
44. Nazha A, Cook R, Vogl DT, Mangan PA, Hummel K, Cunningham K, Luger S, Porter D, Schuster SJ, O'Doherty U, Sell M, Siegel DL, Stadtmauer EA,. Plerixafor and G-CSF versus cyclophosphamide and G-CSF for stem cell mobilization in patients with multiple myeloma 51st. American Society of Hematology Annual Meeting and Exposition. New Orleans, LA, 2009: Poster 2146.
45. Hubel K, Fresen MM, Salwender H, Basara N, Beier R, Theurich S, Christopeit M, Bogner C, Galm O, Hartwig R, Heits F, Lordick F, Rosler W, Wehler D, Zander AR, Albert MH, Dressler S, Ebinger M, Frickhofen N, Hertenstein B, Kiehl M, Liebler S, von, Lilienfeld-Toal M, Weidmann E, Weigelt C, Lange F, Kroger N,. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011; 46: 1045-1052.
46. Jantunen E, Kvalheim G,. Mobilization strategies in hard-to-mobilize patients with lymphoid malignancies. Eur J Haematol 2010; 85: 463-471.
47. Pusic I, Jiang SY, Landua S, Uy GL, Rettig MP, Cashen AF, Westervelt P, Vij R, Abboud CN, Stockerl-Goldstein KE, Sempek DS, Smith AL, DiPersio JF,. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008; 14: 1045-1056.
48. Akhtar S, Weshi AE, Rahal M, Khafaga Y, Tbakhi A, Humaidan H, Maghfoor I,. Factors affecting autologous peripheral blood stem cell collection in patients with relapsed or refractory diffuse large cell lymphoma and Hodgkin lymphoma: a single institution result of 168 patients. Leuk Lymphoma 2008; 49: 769-778. (Pubitemid 351517224)
49. Kuittinen T, Nousiainen T, Halonen P, Mahlamaki E, Jantunen E,. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-912. (Pubitemid 38660123)
50. Mendrone A, Jr, Arrais CA, Saboya R, Chamone Dde A, Dulley FL,. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008; 39: 187-192.
51. Pavone V, Gaudio F, Console G, Vitolo U, Iacopino P, Guarini A, Liso V, Perrone T, Liso A,. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 37: 719-724.
52. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K, Goldschmidt H, Ho AD,. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.
53. Basak GW, Knopinska-Posluszny W, Matuszak M, Kisiel E, Hawrylecka D, Szmigielska-Kaplon A, Urbaniak-Kujda D, Dybko J, Zielinska P, Dabrowska-Iwanicka A, Werkun J, Rzepecki P, Wroblewska W, Wiktor-Jedrzejczak W,. Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)-Polish compassionate use experience. Ann Hematol 2011; 90: 557-568.
54. Selleslag D, Dierickx D, Breems DA, Huynh P, Van De Velde A, Meers S, Brouwer E, Mertens A,. Plerixafor in poor stem cell mobilizers: the Belgian compassionate use program. Acta Clin Belg 2011; 66: 200-204.
55. Arcaini L, Laszlo D, Rizzi S, Balzarotti M, Antoniazzi F, Zilioli VR, Guggiari E, Farina L, Todisco E, Bonfichi M, Alamos SM, Rossi G, Martinelli G, Morra E,. Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experience. Leuk Res 2011; 35: 712-714.
56. D'Addio A, Curti A, Worel N, Douglas K, Motta MR, Rizzi S, Dan E, Taioli S, Giudice V, Agis H, Kopetzky G, Soutar R, Casadei B, Baccarani M, Lemoli RM,. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011; 46: 356-363.
57. Jantunen E, Penttila K, Pyorala M, Mahlamaki E, Kuittinen T, Nousiainen T,. Addition of plerixafor to a chemotherapy plus G-CSF mobilization in hard-to-mobilize patients. Bone Marrow Transplant 2011; 46: 308-309.
58. Josefsen D, Rechnitzer C, Parto K, Kvalheim G,. The use of plerixafor for blood stem cell mobilization reduces the frequency of mobilization failure in patients planned to undergo autologous stem cell transplantation. Eur Haematol 2010; 4: 24-29.
59. Segel E, Sorensen B, d'Amore F, Hokland P,. Successful peripheral blood stem cell harvest in mobilization-refractory lymphoma patients. Bone Marrow Transplant 2010; 45 (Suppl. 2): S258.
60. Jantunen E, Lemoli RM,. Preemptive use of plerixafor in difficult-to-mobilize patients: an emerging concept. Transfusion 2012; 52: 906-914.
61. Stiff P, Gingrich R, Luger S, Wyres MR, Brown RA, LeMaistre CF, Perry J, Schenkein DP, List A, Mason JR, Bensinger W, Wheeler C, Freter C, Parker WRL, Emmanouilides C,. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000; 26: 471-481.
62. Rick O, Beyer J, Kingreen D, Kuhl JS, Zingsem J, Huhn D, Siegert W, Schwella N,. Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Ann Hematol 2000; 79: 681-686. (Pubitemid 32016388)
63. Watts MJ, Sullivan AM, Leverett D, Peniket AJ, Perry AR, Williams CD, Devereux S, Goldstone AH, Linch DC,. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol 1998; 16: 1554-1560. (Pubitemid 28175780)
64. Abhyankar S, Dejarnette S, Aljitawi O, Ganguly S, Merkel D, McGuirk J,. A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor. Bone Marrow Transplant 2012; 47: 483-487.
65. Vishnu P, Roy V, Paulsen A, Zubair AC,. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2011; 52: 55-62.
66. Li J, Hamilton E, Vaughn L, Graiser M, Renfroe H, Lechowicz MJ, Langston A, Prichard JM, Anderson D, Gleason C, Lonial S, Flowers CR, Kaufman JL, Waller EK,. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011; 51: 2175-2182.
67. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA,. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729-736.
68. Tanhehco YC, Adamski J, Sell M, Cunningham K, Eisenmann C, Magee D, Stadtmauer EA, O'Doherty U,. Plerixafor mobilization leads to a lower ratio of CD34+ cells to total nucleated cells which results in greater storage costs. J Clin Apher 2010; 25: 202-208.
69. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV,; International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009; 114: 1729-1735.
70. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, Litzow MR, Fonseca R, Roy V, Rajkumar SV, Gertz MA,. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007; 21: 2035-2042. (Pubitemid 47299979)
71. Paripati H, Stewart AK, Cabou S, Dueck A, Zepeda VJ, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis JF, Boesiger J, Torloni AS, Fonseca R, Bergsagel PL,. Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma. Leukemia 2008; 22: 1282-1284. (Pubitemid 351833805)
72. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Korbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de, Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S,. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 718-723.
73. Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Blade J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S,; International Myeloma Working Group. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood 2011; 117: 6063-6073.
74. Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Blade J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA,; MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366: 1759-1769.
75. Kean LS, Sen S, Onabajo O, Singh K, Robertson J, Stempora L, Bonifacino AC, Metzger ME, Promislow DE, Mattapallil JJ, Donahue RE,. Significant mobilization of both conventional and regulatory T cells with AMD3100. Blood 2011; 118: 6580-6590.
76. Donahue RE, Jin P, Bonifacino AC, Metzger ME, Ren J, Wang E, Stroncek DF,. Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009; 114: 2530-2541.
77. Porrata LF, Gertz MA, Geyer SM, Litzow MR, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Lacy MQ, Dispenzieri A, Snow DS, Markovic SN,. The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2004; 18: 1085-1092. (Pubitemid 38786967)
78. Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Litzow MR, Winters JL, Markovic SN,. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol Blood Marrow Transplant 2008; 14: 807-816. (Pubitemid 351773157)
79. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN,. Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629-633. (Pubitemid 34539239)
80. Porrata LF, Litzow MR, Inwards DJ, Gastineau DA, Moore SB, Pineda AA, Bundy KL, Padley DJ, Persky D, Ansell SM, Micallef IN, Markovic SN,. Infused peripheral blood autograft absolute lymphocyte count correlates with day 15 absolute lymphocyte count and clinical outcome after autologous peripheral hematopoietic stem cell transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 291-298. (Pubitemid 38256560)
81. Yoon DH, Sohn BS, Jang G, Kim EK, Kang BW, Kim C, Kim JE, Kim S, Lee DH, Lee JS, Park SJ, Park CJ, Huh J, Suh C,. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma. Transfusion 2009; 49: 1890-1900.
82. Wang XN, Haniffa MA, Holtick U, Collin MP, Jackson G, Hilkens CM, Holler E, Edinger M, Hoffmann P, Dickinson AM,. Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming. Transplantation 2009; 88: 188-197.
83. Damon LE,. Mobilization of hematopoietic stem cells into the peripheral blood. Expert Rev Hematol 2009; 2: 717-733.
84. Leotta S, Poidomani M, Mauro E, Spadaro A, Marturano E, Milone G,. AMD3100 for urgent PBSC mobilization and allogeneic transplantation from a normal donor after failed marrow harvest. Bone Marrow Transplant 2011; 46: 314-316.
85. Lemery SJ, Hsieh MM, Smith A, Rao S, Khuu HM, Theresa D, Viano JM, Cook L, Goodwin R, Boss C, Calandra G, Geller N, Tisdale J, Childs R,. A pilot study evaluating the safety and CD34+ cell mobilizing activity of escalating doses of plerixafor in healthy volunteers. Br J Haematol 2011; 153: 66-75.
86. Tavor S, Petit I,. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia? Semin Cancer Biol 2010; 20: 178-185.
87. Nervi B, Ramirez P, Rettig MP, Uy GL, Holt MS, Ritchey JK, Prior JL, Piwnica-Worms D, Bridger G, Ley TJ, DiPersio JF,. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206-6214.
88. Zeng Z, Shi YX, Samudio IJ, Wang RY, Ling X, Frolova O, Levis M, Rubin JB, Negrin RR, Estey EH, Konoplev S, Andreeff M, Konopleva M,. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215-6224.
89. Juarez J, Dela Pena A, Baraz R, Hewson J, Khoo M, Cisterne A, Fricker S, Fujii N, Bradstock KF, Bendall LJ,. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia 2007; 21: 1249-1257. (Pubitemid 46831814)
90. Juarez J, Bradstock KF, Gottlieb DJ, Bendall LJ,. Effects of inhibitors of the chemokine receptor CXCR4 on acute lymphoblastic leukemia cells in vitro. Leukemia 2003; 17: 1294-1300. (Pubitemid 36857336)
91. Parameswaran R, Yu M, Lim M, Groffen J, Heisterkamp N,. Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist. Leukemia 2011; 25: 1314-1323.
92. Micallef IN, Stiff PJ, DiPersio JF, Maziarz RT, McCarty JM, Bridger G, Calandra G,. Successful stem cell remobilization using plerixafor (Mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009; 15: 1578-1586.